Generated Q2 2025 Net Revenue of $37.2 million and year-to-date revenue of $76.1 million; reaffirmed 2025 Net Revenue Guidance of $153 million - $163 million Delivered record year-to-date 2025 Adjusted EBITDA of $7.9 million, raised full-year 2025 Adjusted EBITDA Guidance from $4.0...
Related Questions
What are the key drivers behind the record year‑to‑date 2025 Adjusted EBITDA of $7.9 million?
What is the market's reaction to the raised full-year 2025 Adjusted EBITDA guidance and how might it impact the stock price?
What upcoming commercial milestones or product launches could influence future revenue and earnings?
How does Q2 2025 net revenue of $37.2 million compare to analyst expectations and prior quarters?
How does Heron Therapeutics' performance compare to peers in the biotech/therapeutics sector?
How will the reaffirmed 2025 Net Revenue guidance affect HRTX's valuation and price target?
Are there any changes in cash flow, working capital, or cash conversion cycle that could affect liquidity?
What is the implied upside or downside based on the updated guidance versus the current market price?
What potential risks (regulatory, competitive, reimbursement) could jeopardize meeting the full‑year guidance?
How does the current sentiment score of 65 align with analyst sentiment and could it affect trading volume?